每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析

目的 比较每周脂质体紫杉醇联合替吉奥与奥沙利铂联合替吉奥一线治疗老年晚期胃癌的疗效及安全性。方法 将119例老年晚期胃癌患者随机分为两组,A组62例患者采用每周脂质体紫杉醇联合替吉奥方案,B组57例患者采用奥沙利铂联合替吉奥方案。比较两组患者的近期疗效、无疾病进展时间（PFS）、总生存时间（OS）、体能状态和不良反应。结果 A组患者的客观缓解率（ORR）、疾病控制率（DCR）、PFS、OS分别为22.0%、69.5%、6.4月和10.8月,B组分别为25.0%、67.9%、6.4月和10.4月,两组间差异均无统计学意义（P均>0.05）。B组Ⅰ~Ⅱ级胃肠道反应、Ⅰ~Ⅱ级和Ⅲ~Ⅳ级外周神经毒性发生率均较A组严重（P均<0.05）。结论 每周脂质体紫杉醇联合替吉奥治疗老年晚期胃癌的近期疗效与传统的奥沙利铂联合替吉奥相似,但前者患者的耐受性更好,可推荐作为老年晚期胃癌患者治疗的首要选择。     

替吉奥联合紫杉醇脂质体治疗晚期胃癌的临床观察

目的观察和评价替吉奥联合紫杉醇脂质体治疗晚期胃癌的临床疗效和安全性。方法17例初治和16例复治的晚期胃癌患者采用替吉奥联合紫杉醇脂质体方案治疗，替吉奥胶囊80mg／（m2·d），分2次口服，d1～d14；紫杉醇脂质体135mg／m2，分别于第1天和第8天静脉滴注。治疗2个周期后进行疗效评价。结果33例患者中，CR0例（0％），PR16例（48．5％），SD9例（27．3％）．PD8例（24．2％），RR48．5％，CBR75．8％。主要毒副反应是白细胞减少、贫血及胃肠道反应。结论替吉奥联合紫杉醇脂质体是治疗晚期胃癌的一种较为理想的化疗方案，该方案毒副反应较少，绝大多数患者可以耐受。     

紫杉醇联合替吉奥胶囊治疗晚期胃癌的临床观察

目的观察紫杉醇联合替吉奥胶囊(维康达)方案治疗晚期胃癌的临床疗效及不良反应。方法 46例晚期胃癌患者采用以下方案化疗:替吉奥胶囊每天80 mg/m2,分2次,餐后口服,d1～d14;紫杉醇60 mg/m2,d1、d8、d15,静脉滴注3 h。28 d为1个周期,至少完成2个周期。按RECIST1.1标准评价客观疗效和不良反应。结果 46例患者均可以评价疗效。CR 3例(6.5%),PR 18例(39.1%),SD 14例(30.4%),PD 11例(23.9%),RR 45.6%,DCR 76.0%。中位疾病进展时间(mT-TP)为9.5个月,中位生存期(MST)为12.6个月。不良反应主要是骨髓抑制、胃肠道反应、脱发及口腔黏膜炎。结论紫杉醇联合替吉奥方案治疗晚期胃癌的疗效较好,不良反应可以耐受,值得进一步研究应用。     

培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案二线治疗晚期胃癌的临床研究

目的:观察培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案在晚期胃癌二线治疗中的近期疗效和安全性。方法:经病理组织学或细胞学确诊的60例晚期胃癌患者随机分为两组,A组28例(培美曲塞500mg/m2 iv d1,奥沙利铂85mg/m2 iv d1),B组32例(紫杉醇脂质体135mg/m2 iv d1,替吉奥40mg/m2 bid d1~14),21天为1周期,2周期后评价疗效及不良反应发生情况。结果:60例患者均可评价疗效,Ａ组和Ｂ组有效率分别是14.29％和18.75％(P＞0.05),疾病控制率分别是46.43％和56.25％(P＞0.05),中位TTP分别为5.8个月和6.2个月(P＞0.05)。化疗不良反应总体上均可耐受,A组乏力、皮疹和脱发发生率为78.57%、35.71%和25.0%(P＜0.05),B组白细胞减少、血小板减少发生率分别为68.75%和62.50%(P＜0.05)。结论:培美曲塞联合奥沙利铂方案和紫杉醇脂质体联合替吉奥方案二线治疗晚期胃癌的近期疗效相当,不良反应可耐受,可以作为晚期胃癌的有效姑息治疗方案。     

替吉奥胶囊治疗蒽环类和（或）紫杉醇化疗失败的晚期乳腺癌疗效观察

目的探讨替吉奥胶囊（S-1）治疗蒽环类和（或）紫杉醇治疗失败的乳腺癌的近期疗效和不良反应。方法将15例晚期乳腺癌患者给予替吉奥胶囊（S-1）化疗。按RECIST标准评价近期疗效,WHO标准评价不良反应。结果获得完全缓解0例,部分缓解6例,稳定5例,进展4例,总有效率为40%;全组无治疗相关性死亡。结论替吉奥胶囊对蒽环类和（或）紫杉醇治疗失败的晚期乳腺癌临床缓解率高,不良反应轻,患者耐受性好,有可能成为化疗失败的转移性乳腺癌患者的补救药物。     

多西紫杉醇联合替吉奥胶囊治疗晚期食管胃交界腺癌的临床观察

目的:探讨多西紫杉醇联合替吉奥胶囊治疗晚期食管胃交界腺癌的临床疗效和不良反应。方法:2009年1月—2011年1月经病理学确诊的58例晚期食管胃交界腺癌患者接受多西紫杉醇联合替吉奥胶囊治疗:多西紫杉醇35mg/m2静脉注射d1和d8,替吉奥胶囊胶囊每天70mg/m2d1～14,每3周为1个化疗周期。每2个化疗周期评价近期疗效。每个化疗周期后评价不良反应。对所有患者进行随访,评估生存情况。结果:58例患者均可评价疗效,其中完全缓解5例(8.6%)、部分缓解21例(36.2%),疾病稳定18例(31.0%),疾病进展14例(24.1%),有效率为44.8%(26/58)。中位TTP为8.0个月,MST为10.5个月。主要不良反应包括骨髓抑制、口腔炎、手足综合征和胃肠不良反应等。Ⅲ～Ⅳ级中性粒细胞减少发生率为25.9%(15/58)。结论:多西紫杉醇联合替吉奥胶囊治疗晚期食管胃交界腺癌的近期疗效较好,不良反应可以耐受。     

小剂量阿帕替尼联合紫杉醇脂质体与雷替曲塞二线治疗晚期胃癌的疗效及安全性

目的探讨小剂量阿帕替尼联合紫杉醇脂质体与雷替曲塞二线治疗晚期胃癌的疗效及安全性。方法选取2015年3月至2017年10月间常州市肿瘤医院收治的18例一线化疗后进展或病灶缓解后再进展的胃腺癌或胃食管结合部腺癌患者,均接受甲磺酸阿帕替尼片抗血管生成治疗联合紫杉醇脂质体与雷替曲塞化疗。2个周期后,评价患者的临床疗效及治疗相关不良反应。结果患者共完成治疗69个周期(1～6个周期),平均3. 8个周期。其中部分缓解4例,稳定6例,进展8例,有效率为22. 2%,疾病控制率为55. 6%,患者中位无进展生存时间为92. 9d(52～306d)。患者无治疗相关死亡。常见不良反应为中性粒细胞减少、恶心、呕吐、乏力、药物性高血压或原有高血压加重及手足综合征。其中Ⅲ级高血压3例,经缬沙坦氨氯噻嗪片口服后血压控制良好,疗效均为部分缓解。Ⅲ级手足综合征及口腔黏膜炎出现于同1例稳定患者,经短时停药及促黏膜修复治疗后好转。Ⅰ～Ⅱ级乏力患者8例,经每日静脉或口服使用小剂量糖皮质激素治疗后症状好转;Ⅲ级乏力患者用药后一月余渐出现淡漠症状,甲状腺功能减退,口服补充甲状腺素后症状好转。结论小剂量阿帕替尼联合紫杉醇脂质体与雷替曲塞二线治疗晚期胃癌有一定疗效,耐受性好。     

多西紫杉醇联合替吉奥胶囊治疗晚期胃癌的近期疗效

目的：探讨多西紫杉醇联合替吉奥胶囊治疗晚期胃癌近期疗效及毒副作用。方法按照随机数字表法,将38例晚期胃癌患者均分为实验组和对照组,对照组患者采用多西紫杉醇、亚叶酸钙联合氟尿嘧啶方案化疗,实验组患者采用多西紫杉醇联合替吉奥胶囊方案化疗,对比2组近期疗效、不良反应发生情况以及可评价肿瘤进展时间。结果实验组患者治疗总有效率显著高于对照组,差异具有显著性（P＜0．05）;两组患者不良反应发生率及严重程度对比,差异无统计学意义（P＞0．05）;两组患者可评价肿瘤进展时间对比,差异无统计学意义（P＞0．05）。结论多西紫杉醇联合替吉奥胶囊治疗晚期胃癌能够有效提高近期疗效,且不会明显增加不良反应,也不会对可评价肿瘤进展时间产生明显影响。     

替吉奥胶囊联合奥沙利铂治疗晚期食管癌的临床观察

目的观察替吉奥胶囊联合奥沙利铂治疗晚期食管癌患者的疗效和不良反应。方法 27例晚期食管癌患者采用替吉奥胶囊联合奥沙利铂方案治疗,每3周重复1次,治疗3个周期后评价疗效。结果 27例患者均完成6个周期化疗。其中完全缓解1例（3.7%）,部分缓解12例（44.4%）,近期有效率48.1%。主要不良反应为血液学毒性、胃肠道反应和感觉神经毒性,无化疗相关性死亡。结论替吉奥胶囊联合奥沙利铂治疗晚期食管癌,疗效肯定,患者耐受性良好,可作为晚期食管癌患者化疗的选择方案。     

奥沙利铂联合紫杉醇脂质体治疗晚期胃癌的疗效分析

目的 探讨奥沙利铂联合紫杉醇脂质体或替吉奥治疗晚期胃癌的临床疗效及不良反应.方法 选取46例晚期胃癌患者作为研究对象.按照随机数字表法将46例晚期胃癌患者随机分为A组和B组,每组23例.其中,A组患者接受奥沙利铂联合紫杉醇脂质体方案化疗,B组患者接受奥沙利铂联合替吉奥方案化疗.比较两组患者的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)和不良反应发生情况.结果 A组患者的ORR为47.8%,DCR为78.3%;B组患者的ORR为43.5%,DCR为69.6%;两组患者的ORR和DCR比较,差异均无统计学意义(P=0.767、0.502).A组和B组患者的中位OS分别为9.4个月和9.5个月,两组比较,差异无统计学意义(P=0.911).A组患者的中位PFS为6.9个月(95%CI:6.2~7.8个月),长于B组患者的5.4个月(95%CI:4.0~5.9个月),差异有统计学意义(P=0.048).两组患者的中性粒细胞减少、血小板减少、贫血、疲劳乏力、腹泻、关节肌肉疼痛、恶心呕吐以及神经毒性的发生率比较,差异均无统计学意义(P﹥0.05).结论 奥沙利铂联合紫杉醇脂质体方案和奥沙利铂联合替吉奥方案治疗晚期胃癌的临床疗效接近,但在晚期胃癌患者的无进展生存期方面,奥沙利铂联合紫杉醇脂质体方案可能优于奥沙利铂联合替吉奥方案.     

Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer

Purpose Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer. Patients and methods Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m² plus cisplatin 35 mg/m² on days 1 and 8 based on a 3-week cycle. Results Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no treatment-related deaths. Conclusion A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.     

周剂量多西紫杉醇联合卡培他滨治疗晚期胃癌的临床观察

目的观察周剂量多西他赛联合卡培他滨治疗晚期胃癌的近期疗效和不良反应。方法 37例晚期胃癌患者采用多西他赛35mg/m2,静脉滴注,第1,8天;卡培他滨1250mg/m2,bid,口服,1～14d,21d为1周期。3周期后评价疗效和不良反应。结果全组37例患者均可评价疗效,其中CR3例（8.1%）,PR19例（51.3%）,SD10例（27.0%）,PD5例（13.5%）,总有效率59.5%。中性粒细胞减少发生率54.0%。中位TTP为6.5个月（3.2～11.5个月）,中位MST为10.3个月（5.8～14.7个月）。结论多西他赛联合卡培他滨治疗晚期胃癌有效率较高,血液学毒性低,近期疗效较好,用药方便、安全,明显提高了患者的生活质量。     

An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer

The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol((R))) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1 : 4 molar ratio) and leucovorin (LV) in patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Paclitaxel 1-h infusion at a dose of 100 mg m(-2) on days 1 and 8 and oral UFT 300 mg m(-2) day(-1) plus LV 90 mg day(-1) were given starting from day 1 for 14 days, followed by a 7-day period without treatment. Treatment was repeated every 21 days. From February 2003 to October 2004, 55 patients were enrolled. The median age was 62 years (range: 32-82). Among the 48 patients evaluated for tumour response, two achieved a complete response and 22 a partial response, with an overall response rate of 50% (95% confidence interval: 35-65%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 4.4 and 9.8 months, respectively. Major grade 3-4 toxicities were neutropenia in 25 patients (45%) and diarrhoea in eight patients (15%). Although treatment was discontinued owing to treatment-related toxicities in nine patients (16%), there was no treatment-related mortality. Weekly paclitaxel plus oral UFT/LV is effective, convenient, and well tolerated in treating patients with advanced gastric cancer.     

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial

Paclitaxel is a cytotoxic agent with proven antitumour activity in metastatic breast cancer. Weekly administration of paclitaxel has demonstrated sustained efficacy together with a more favourable toxicity profile (e.g. less myelotoxicity) than the 3-weekly administration. This study evaluates the activity and toxicity of weekly paclitaxel (Taxol(R)) as first-line chemotherapy in elderly patients (>70 years of age) with hormone-refractory metastatic breast cancer. Patients with metastatic breast cancer received 80 mg/m(2) paclitaxel administered weekly on days 1, 8 and 15 of a 28-day cycle. Additional cycles were given until disease progression, or unacceptable toxicity. A dose increase to 90 mg/m(2) was allowed in the absence of toxicity. 26 Patients received a total of 101 cycles (median 4, range 1-11). 22 patients completed at least two cycles (six administrations). In 23 patients who were evaluable for response, there were 10 partial responses (38%), 9 patients with stable disease (35%), while 4 patients had disease progression (15%). The median duration of response was 194 days (>6 months). Overall treatment was relatively well tolerated, but 8 patients (32%) had to prematurely discontinue treatment because of fatigue. Neuropathy >grade 1 was noted only after five or more cycles in 4 patients. Weekly paclitaxel at this dose and schedule is an effective treatment regimen in the elderly patient with metastatic breast cancer, and is feasible, but yields relevant fatigue in a subset of patients.     

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

PURPOSE: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. PATIENTS AND METHODS: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m(2) by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. RESULTS: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m(2). Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. CONCLUSION: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.     

紫杉醇脂质体或紫杉醇联合5-氟尿嘧啶一线治疗晚期胃癌的临床疗效分析

目的 比较紫杉醇脂质体联合5-氟尿嘧啶(5-Fu)与紫杉醇联合5-Fu一线治疗晚期胃癌的近期疗效、不良反应及预后.方法 经病理或细胞学证实的67例晚期胃癌患者,31例接受紫杉醇脂质体联合5-Fu方案化疗(力扑素组),34例接受紫杉醇联合5-Fu方案化疗(紫杉醇组).按照世界卫生组织(WHO)标准评价近期疗效,按照WHO关于化疗药物不良反应的评价标准评价不良反应.结果 力扑素组和紫杉醇组的客观有效率分别为54.8%和44.1%(P=0.388),中位疾病进展时间分别为5.10和5.20个月(P=O.266),中位生存时间分别为10.07和8.97个月(P=0.186).力扑素组和紫杉醇组的主要不良反应为血液学毒性及恶心呕吐,Ⅲ～Ⅳ度恶心呕吐的发生率为16.1%和50.0%(P=0.038),肌肉关节痛的发生率为9.7%和29.4%(P=0.047).结论 紫杉醇脂质体联合5-Fu使用方便,与紫杉醇联合5-Fu一线治疗晚期胃癌疗效相当,但Ⅲ～Ⅳ度不良反应发生率较低.     

Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

Background Paclitaxel scheduled every 3 weeks has shown a response rate of ∼20% for gastric cancer, with modest hematological toxicity. Weekly administration of paclitaxel in patients with breast or ovarian cancer has shown equivalent efficacy and milder toxicity compared with an every-3 week schedule. We investigated, retrospectively, the antitumor effects and toxicity profiles of weekly paclitaxel for patients with metastatic or recurrent gastric cancer in clinical practice. Methods In 38 patients who had metastatic or recurrent histologically confirmed gastric cancer and a history of one prior chemotherapy regimen, other than paclitaxel or docetaxel, paclitaxel (8mg/m²) was administered weekly, three times every 4 weeks, with short-term premedication. Results All 38 patients had had prior chemotherapy that included 5-fluorouracil, the fluoropyrimidine anticancer drug S-1, or cisplatin. The median number of courses in the present regimen was 6 (range, 1–44+). Dose intensity was 5mg/m² per week, corresponding to 92% of the planned dose (6mg/m² per week). The overall response rate was 24% (6/25) in measurable lesions, and pleural effusion and ascites disappeared in 2 of 7 patients (29%) and in 3 of 21 patients (14%), respectively. Median survival time was 151 days from the commencement of this treatment, with a median follow-up period of 260 days. Grade 3 or 4 leukopenia and neutropenia were observed in 11 (29%) and 12 (32%) patients, respectively. Seven patients (18%) died within 30 days of the last administration of paclitaxel. Conclusion Weekly paclitaxel seems to be active as second-line chemotherapy against metastatic and recurrent gastric cancer. Further study is needed to confirm the efficacy and safety of weekly paclitaxel.     

紫杉醇联合卡培他滨或替加氟治疗晚期胃癌的疗效及安全性对比研究

目的观察比较紫杉醇联合卡培他滨方案和紫杉醇联合替加氟方案治疗晚期胃癌的临床疗效和安全性。方法 52例经病理证实的晚期胃癌患者分为A组（24例）和B组（28例）。A组：紫杉醇80~90 mg/m2,静脉滴注,第1、8天;卡培他滨1 000mg/m2,口服,2次/天,第1~14天;21 d为1个周期。B组：紫杉醇80~90 mg/m2,静脉滴注,第1、8天;亚叶酸钙200 mg/m2,静脉滴注2 h后予替加氟0.8~1.0 g,静脉滴注,第2~6天;21 d为1个周期。每例患者治疗至少2个周期。按RE-CIST标准评价客观疗效,按WHO标准评价不良反应。结果 52例患者均可评价疗效。A组24例,客观有效率（RR）为50.0%,中位进展时间（TTP）5.9个月,中位生存期（MST）12.4个月;B组28例,有效率39.3%,TTP 5.8个月,MST11.8个月。两组疗效无统计学差异（P〉0.05）。两组的主要毒副反应为骨髓抑制、胃肠道反应,多数为Ⅰ~Ⅱ度;A组手足综合征发生率为29.2%,B组未出现,差异有显著性（P〈0.01）。结论紫杉醇联合卡培他滨与紫杉醇联合替加氟治疗晚期胃癌的疗效相近,毒副反应均可耐受,但前一方案用药更方便,是治疗晚期胃癌的较好方案之一。     

Weekly paclitaxel in metastatic breast cancer patients: a phase II study

AIMS ANID BACKGROUND: Paclitaxel, a microtubule inhibitor, is one of the most active drugs in metastatic breast cancer. A weekly schedule, at a median dose-intensity of 91 mg/m2, is effective and has less side effects than a 3-week schedule. In this phase II study, we evaluated the toxicity and the activity of weekly 1 hr paclitaxel infusions in metastatic breast cancer patients. STUDY DESIGN: Between February 1999 and February 2001, 26 patients with metastatic breast cancer were treated with weekly paclitaxel (60-90 mg/m2/1 hour iv infusion/weekly). The treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, paclitaxel was stopped after 6 months of therapy. RESULTS: At a median follow-up of 18.7 months (range, 6.8-30.8), all patients are assessable for response and toxicity. We obtained 8 partial responses (30.8%), 8 stable disease (30.8%) and 10 disease progression (38.4.%). The overall response was 30.8% (95% CI, 13.1-48.5). The median duration of response was 7.6 months (range, 1.8-12.4); median time to progression was 4.86 months (range, 1.4-12.4); median overall survival was 9.9 months (range, 1.7-29.2+). Treatment was well tolerated. Hematological toxicity was mild and only one patient developed grade 3 anemia. Two patients experienced grade 3 cardiovascular toxicity; both had received anthracycline-based regimens. CONCLUSIONS: In our experience, weekly administration of paclitaxel shows a substantial degree of activity even in pretreated metastatic breast cancer patients. The toxicity profile is favorable.     

紫杉醇单药每周方案治疗老年转移性乳腺癌的临床疗效观察

目的分析紫杉醇单药每周方案治疗老年转移性乳腺癌的疗效及安全性。方法本科于2004年至2007年间收治了33例经病理证实的晚期转移性乳腺癌患者,年龄65～74岁,中位年龄68岁,复发转移后初治的19例患者为一线治疗组,既往接受其他化疗的14例患者为二线治疗组,两组均接受紫杉醇单药治疗80mg／m^2,第1、8、15天应用,28d为1个周期。应用紫杉醇前常规采用地塞米松、苯海拉明、西咪替丁等抗过敏处理。应用SPSS10．0统计软件进行统计学处理,采用Fisher检验比较组间的疗效和生存情况。结果可评价疗效病例33例,总有效率为39％,其中完全缓解（complete response,CR）1例（3％）,部分缓解（partial response,PR）12例（36％）,稳定（stable disease,SD）9例（27％）、进展（progressing disease,PD）11例（33％）。一线治疗组CR1例,PR7例;二线治疗组CR0例,PR5例,两组疗效差异无统计学意义（x^2=0．13,P=0．26）。中位化疗周期为6个,临床受益（CR＋PR＋SD）22例（67％）,中位肿瘤进展时间（TTP）为5．8个月,中位总生存时间（OS）是16．1个月。不良反应主要为骨髓抑制和神经肌肉毒性,毒性反应分级为Ⅰ～Ⅱ度,未见严重不良反应。结论对于老年转移性乳腺癌患者,单药紫杉醇每周方案疗效是肯定的,耐受性良好,极少引起严重的血液学及非血液学毒性,对于一般情况差的老年患者仍然有效。